Trials / Terminated
TerminatedNCT01480245
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy
An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of GSK2402968 in Subjects With Duchenne Muscular Dystrophy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 233 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 5 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore long-term safety, tolerability and efficacy of GSK2402968 in DMD subjects who previously participated in either DMD114117 or DMD114044.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK2402968 | 6mg/kg/week |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2011-11-28
- Last updated
- 2017-03-23
Locations
59 sites across 24 countries: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Norway, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01480245. Inclusion in this directory is not an endorsement.